Literature DB >> 29906213

Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.

Hitomi Umeguchi1, Hiromasa Takenoshita1, Hiroshi Inoue1, Yuki Kurihara1, Chihiro Sakaguchi1, Seiichi Yano1, Nao Hasuzawa1, Shohei Sakamoto1, Ryuichi Sakamoto1, Kenji Ashida1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29906213     DOI： 10.1200/JOP.18.00076

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  5 in total

Review 1.  Endocrine complications of immunotherapies: a review.

Authors:  Rosie Hattersley; Melanie Nana; Andrew J Lansdown
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

2.  Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up.

Authors:  Ramona Dadu; Theresa E Rodgers; Van A Trinh; Elizabeth Helen Kemp; Trisha D Cubb; Sapna Patel; Julie M Simon; Elizabeth M Burton; Hussein Tawbi
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 3.  Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.

Authors:  Naoko Okura; Mai Asano; Junji Uchino; Yoshie Morimoto; Masahiro Iwasaku; Yoshiko Kaneko; Tadaaki Yamada; Michiaki Fukui; Koichi Takayama
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

4.  Pembrolizumab-Associated Hypoparathyroidism: A Single Case Report.

Authors:  Israa Mahmood; Nitesh D Kuhadiya; Michael Gonzalaes
Journal:  AACE Clin Case Rep       Date:  2020-11-28

Review 5.  Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.

Authors:  Shintaro Iwama; Tomoko Kobayashi; Hiroshi Arima
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.